Randomized Phase 2 Study Of IMC-A12 For Advanced Breast Cancer Commences Patient Enro

[News]

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12, ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in women with advanced breast cancer has commenced patient enrollment.

More... (http://www.medicalnewstoday.com/articles/123247.php)